Skip to main content
. 2023 Aug 1;5(5):613–624. doi: 10.1016/j.jaccao.2023.05.011

Figure 2.

Figure 2

GnRH Antagonist vs Agonist and MACE

Forest plot of ORs and corresponding 95% credible interval (CrI) for gonadotropin-releasing hormone (GnRH) antagonists and major adverse cardiovascular event (MACE) compared with GnRH agonists. HERO = A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer; PRONOUNCE = A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease.